Why invest in Hofseth BioCare?

A strong ESG-profile, and patented processes coupled with world class R&D with diversified pipelines including research programs on asthma, COVID-19 and gastro

Ticker: HBC
Last updated: 03.12.2020 13:34
Latest

9.20 NOK

Change

0.10

Change (%)

1.10

Share information

IR contact

News

Reports

Governance

OVI 3832 01
LATEST REPORT

Q3 2020 Report

Download our latest report, or view all quarterly and yearly reports in the archives.

Download Q3 2020
All reports
16:9
NEXT UP

Financial calendar

Q4 Quarterly report 2020
05.02.2021

Annual Report 2020
19.03.2021

Investor presentation

Download our latest investor presentation in PDF-format for a even deeper insight into our current ongoing business and future potential.

Download presentation

Stock exchange notices

View all notices

HBC adds ex-Johnson & Johnson Senior Commercial leader, Will Urban-Smith, to its Sales & Marketing team in the Consumer Health division

02.12.2020

Significant exclusive distribution agreement with IMCD for 16 territories globally including the USA & Canada

01.12.2020

Boosts Sales & Marketing in its Consumer Health division by hiring ex-Novartis and ex-GSK senior executive Andy Gill

30.11.2020

SUPPLEMENTARY ELECTIONS TO BOARD AND AUDIT COMMITTEE – NOTICE OF EGM

11.11.2020

COMPLETED EXTRAORDINARY GENERAL MEETING AND APPROVED SUBSEQUENT OFFERING

11.11.2020

Contact investor relations

James Berger
James Berger
Head of Investor Relations & Strategy
+41 79 950 10 34 jb@hofsethbiocare.no
Crawford Currie
Dr. Crawford Currie
Medical R&D & Investor Relations
+44 7968 195497 cc@hofsethbiocare.no